{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T07:14:20Z","timestamp":1783754060837,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.prro.2026.06.015","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:40:16Z","timestamp":1783752016000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cCumulative incidence of toxicity between 2 and 5 years following SBRT to the prostate and pelvis nodes in patients with high-risk prostate cancer \u201c"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-9806","authenticated-orcid":false,"given":"Constanza","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Duclos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Man Git","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ackeem","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Patrocinio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Souhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.prro.2026.06.015_bib0001","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"issue":"15","key":"10.1016\/j.prro.2026.06.015_bib0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.prro.2026.06.015_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.prro.2026.06.015_bib0004","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.06.015_bib0005","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fonc.2014.00240","article-title":"Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.prro.2026.06.015_bib0006","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.prro.2026.06.015_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canrad.2023.07.014","article-title":"Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes","volume":"28","author":"Faria","year":"2024","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.prro.2026.06.015_bib0008","article-title":"NCCN Clinical Practice guidelines in Oncology","volume":"2025","year":"2025","journal-title":"Prostate Cancer"},{"issue":"4","key":"10.1016\/j.prro.2026.06.015_bib0009","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ijrobp.2025.08.029","article-title":"Androgen Deprivation Therapy (ADT) and High Dose Definitive Radiotherapy (RT) \u00b1 Whole Pelvic RT in Patients with Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: Early Results of a Phase III Randomized Controlled Trial","volume":"123","author":"Roach","year":"2025","journal-title":"International Journal of Radiation Oncology*Biology*Physics."},{"issue":"4","key":"10.1016\/j.prro.2026.06.015_bib0010","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijrobp.2015.03.021","article-title":"Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy","volume":"92","author":"Harris","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.prro.2026.06.015_bib0011","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.prro.2017.01.003","article-title":"Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy","volume":"7","author":"Faria","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.prro.2026.06.015_bib0012","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.prro.2015.05.002","article-title":"Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes","volume":"5","author":"Lecavalier-Barsoum","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.06.015_bib0013","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2009-05-29. 2009."},{"issue":"6","key":"10.1016\/j.prro.2026.06.015_bib0014","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/j.prro.2020.06.012","article-title":"Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer","volume":"10","author":"Faria","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"10.1016\/j.prro.2026.06.015_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.eururo.2024.08.032","article-title":"Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial","volume":"87","author":"Niazi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.06.015_bib0016","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fonc.2017.00157","article-title":"Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?","volume":"7","author":"Kataria","year":"2017","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.prro.2026.06.015_bib0017","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S1470-2045(18)30588-6","article-title":"Pelvic radiotherapy in prostate cancer: an unresolved question","volume":"19","author":"Delouya","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.prro.2026.06.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2023.06.1512","article-title":"Evaluation of kV Triggered Fiducial Tracking for Prostate SBRT Intrafraction Motion Management","volume":"117","author":"Harari","year":"2023","journal-title":"International Journal of Radiation Oncology*Biology*Physics."},{"key":"10.1016\/j.prro.2026.06.015_bib0019","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0167-8140(22)04435-8","article-title":"155: Calcification and Image Guided Radiotherapy for Localized High-Risk Prostate Cancer","volume":"174","author":"Faria","year":"2022","journal-title":"Radiotherapy and Oncology"},{"issue":"12","key":"10.1016\/j.prro.2026.06.015_bib0020","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1002\/mp.12633","article-title":"Implanted fiducial markers are no longer needed for prostate cancer radiotherapy","volume":"44","author":"Njeh","year":"2017","journal-title":"Med Phys"},{"issue":"4","key":"10.1016\/j.prro.2026.06.015_bib0021","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ijrobp.2025.08.034","article-title":"Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)","volume":"123","author":"Ratnakumaran","year":"2025","journal-title":"International Journal of Radiation Oncology*Biology*Physics."},{"issue":"16","key":"10.1016\/j.prro.2026.06.015_bib0023","first-page":"TPS5132","volume":"43","author":"Loblaw","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.prro.2026.06.015_bib0024","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ijrobp.2008.02.030","article-title":"Reporting late rectal toxicity in prostate cancer patients treated with curative radiation treatment","volume":"72","author":"Faria","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.prro.2026.06.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.prro.2026.06.015_bib0026","article-title":"Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer","volume":"7","author":"Natesan","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"10.1016\/j.prro.2026.06.015_bib0027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.prro.2023.11.008","article-title":"Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (\u2265100 cc) Glands","volume":"14","author":"Hurwitz","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.prro.2026.06.015_bib0028","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.06.015_bib0029","article-title":"Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer","volume":"45","author":"Ong","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"10.1016\/j.prro.2026.06.015_bib0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ijrobp.2024.06.003","article-title":"Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate","volume":"120","author":"Singh","year":"2024","journal-title":"International Journal of Radiation Oncology*Biology*Physics."},{"key":"10.1016\/j.prro.2026.06.015_bib0031","article-title":"PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT","volume":"58","author":"Pathmanathan","year":"2026","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.prro.2026.06.015_bib0032","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2024.12.018","article-title":"Pelvic Regional Control With 25 Gy in 5 Fractions in Stereotactic Radiation Therapy for High-Risk Prostate Cancer: Pooled Prospective Outcomes From the SHARP Consortium","volume":"122","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026002122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026002122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:40:21Z","timestamp":1783752021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850026002122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S1879850026002122"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2026.06.015","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cCumulative incidence of toxicity between 2 and 5 years following SBRT to the prostate and pelvis nodes in patients with high-risk prostate cancer \u201c","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2026.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}